

Are your **MRI contrast agents** cost-effective?

Learn more about generic **Gadolinium-Based Contrast Agents**.



AJNR

**Risk of Acute Kidney Injury with
Consecutive, Multidose Use of Iodinated
Contrast in Patients with Acute Ischemic
Stroke**

Z.Y. Jia, S.X. Wang, L.B. Zhao, Y.Z. Cao, H.B. Shi and S.
Liu

This information is current as
of April 19, 2024.

AJNR Am J Neuroradiol 2019, 40 (4) 652-654
doi: <https://doi.org/10.3174/ajnr.A5959>
<http://www.ajnr.org/content/40/4/652>

Risk of Acute Kidney Injury with Consecutive, Multidose Use of Iodinated Contrast in Patients with Acute Ischemic Stroke

Z.Y. Jia, S.X. Wang, L.B. Zhao, Y.Z. Cao, H.B. Shi, and S. Liu



ABSTRACT

SUMMARY: Currently, CTA is the imaging technique most frequently used to evaluate acute ischemic stroke, and patients with intracranial large-vessel occlusion usually undergo endovascular treatment. This single-center, prospective, cohort study showed that consecutive, multidose use of contrast during CTA and DSA does not increase the incidence of acute kidney injury in patients with acute ischemic stroke, though acute kidney injury tended to have a higher incidence in the contrast multiexposure group ($P = .172$).

ABBREVIATIONS: AKI = acute kidney injury; AIS = acute ischemic stroke

CTA and CTP are the most frequently used noninvasive vascular imaging techniques to evaluate acute ischemic stroke (AIS).^{1,2} Analyses from a number of observational studies suggest that the risk of contrast-induced acute kidney injury (AKI) secondary to CTA/CTP imaging is relatively low in patients with AIS, particularly those with no history of renal impairment.¹⁻³

Apart from CTA/CTP, most patients with AIS, within the time window of recanalization, undergo intra-arterial thrombectomy, which is associated with exposure to additional iodinated contrast medium during DSA.⁴⁻⁸ Because the potential risk from iodinated contrast exposure is proportional to the dose of contrast medium administered, multiple, consecutive doses of contrast medium could imply a greater risk for AKI.^{9,10} Although several studies have cited data regarding the safety of the consecutive use of contrast medium in patients with AIS for CTA/CTP and DSA, the sample sizes have been small, most of the studies were retrospective, and the definition of AKI differed among the studies.¹¹⁻¹⁴ Hence, AKI induced by consecutive multidosing of contrast medium is still a perceived risk. We therefore performed this prospective study to determine whether consecutive, multidose use

of contrast increases the incidence of AKI compared with its single use in patients with AIS.

MATERIALS AND METHODS

Study Design and Patient Enrollment

This study is a prospective, registered, cohort study performed from September 2016 to September 2017 at a single medical center with the approval of the institutional review board of the center. Informed consent was obtained from all patients or their legal representatives.

Patient inclusion criteria were the following: 1) 18 years of age or older; 2) suspicion of AIS; 3) seen within 6 hours of developing anterior circulation symptoms or within 24 hours of posterior circulation symptoms; 4) no intracranial hemorrhage; and 5) underwent CTA. Exclusion criteria were lack of a baseline creatinine level or lack of a follow-up creatinine level 48 hours after CTA.

Imaging

All imaging was performed on a 64-section CT scanner (Optima CT660, GE Healthcare, Milwaukee, Wisconsin). For CTA, isotonic contrast material (1.5 mL/kg) (iodixanol, 320 mg I/mL, Visipaque 320; GE Healthcare, Piscataway, New Jersey) was injected at a rate of 4 mL/s, followed by a 20-mL saline bolus chaser using a dual-head injector. The upper limit volume of the contrast material was 100 mL.

Endovascular Treatment

Intra-arterial treatment consisted of thrombolysis, mechanical thrombectomy with a stent retriever or aspiration catheter, balloon angioplasty and stent insertion, or carotid artery stent placement. The volume of the contrast (iodixanol, 320 mg I/mL, Visipaque 320) used during the procedure was recorded.

Received September 17, 2018; accepted after revision November 18.

From the Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China.

Zhen Yu Jia and Shao Xian Wang contributed equally to this work.

This work was supported by the Construction Program of Jiangsu Provincial Clinical Research Center Support System (BL 2014084). Clinical Trial Registration: <http://www.clinicaltrials.gov>; NCT03132558.

Please address correspondence to Sheng Liu, MD, PhD, Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Rd, Gulou District, Nanjing, Jiangsu Province 210029, China; e-mail: liusheng@njmu.edu.cn

Indicates open access to non-subscribers at www.ajnr.org

<http://dx.doi.org/10.3174/ajnr.A5959>




FIGURE. Flow chart of the study.

Table 1: Baseline demographics and characteristics^a

| | CTA Group (n = 87) | DSA Group (n = 94) | P Value |
|---|--------------------------|--------------------------|------------|
| Age (yr) (mean) | 66.5 ± 11.4 | 67.2 ± 13.0 | .708 |
| Female sex | 28 (32.2) | 37 (39.4) | .315 |
| Hypertension | 50 (57.5) | 55 (58.5) | .887 |
| Diabetes | 27 (31.0) | 18 (19.1) | .065 |
| Hyperlipidemia | 4 (4.6) | 2 (2.1) | .430 |
| Smoking | 18 (20.7) | 19 (20.2) | .937 |
| Prior stroke | 23 (26.4) | 15 (16.0) | .084 |
| Atrial fibrillation | 10 (11.5) | 47 (50.0) | .000 |
| Heart failure | 1 (1.1) | 10 (10.6) | .010 |
| CKD | 0 (0.0) | 0 (0.0) | 1.000 |
| Previous use of contrast | 4 (4.6) | 3 (3.2) | .712 |
| NSAID | 11 (12.6) | 9 (9.6) | .511 |
| Baseline NIHSS (median) (IQR) | 3 (2–4) | 14 (10–19) | .000 |
| Hemoglobin (mean) (g/L) | 137.9 ± 16.0 | 133.5 ± 16.4 | .707 |
| WBC count (mean) (× 10 ⁹ /L) | 7.4 ± 2.6 | 8.0 ± 2.7 | .121 |
| rtPA | 38 (43.7) | 28 (29.8) | .052 |
| mRS score at 3 mo of <3 | 85 (97.7) | 86 (91.5) | .102 |

Note:—CKD indicates chronic kidney dysfunction; NSAID, nonsteroidal anti-inflammatory drugs; IQR, interquartile range; WBC, white blood cells; BUN, blood urea nitrogen.

^a Data are number and percentage unless otherwise indicated.

Definition of AKI

AKI was defined as a >25% increase in the serum creatinine value over the baseline value 48 hours after CTA. The incidence of AKI was compared between patients given iodinated contrast medium for CTA (single exposure, CTA group) versus those given contrast medium for CTA and DSA (consecutive multiexposure, DSA group).

Statistical Analysis

The Student *t* test or the Mann-Whitney *U* test (for unevenly distributed categorical variables) was used to identify the difference in continuous variables. The difference in each of the categorical variables between the 2 groups was tested using a χ^2 or Fisher exact test. Two-tailed *P* < .05 was considered statistically significant.

RESULTS

Altogether, 181 patients with AIS were included in this study (Figure and Table 1), of whom 87 underwent CTA examinations and 94 underwent both CTA and DSA examinations. All patients were given intravenous normal saline for hydration.

The mean serum creatinine levels are shown in Table 2. Nine patients (5.0%) met the diagnostic criteria for AKI: 2 in the CTA group (2.3%) and 7 in the DSA group (7.4%) (*P* = .172). On

Table 2: Incidence of acute kidney injury in 2 study cohorts

| | CTA (n = 87) | CTA + DSA (n = 94) | P Value |
|------------------------------|-----------------|-----------------------|------------|
| Baseline Cr (mg/dL) | 0.84 ± 0.21 | 0.90 ± 0.36 | .137 |
| 48-Hour Cr (mg/dL) | 0.82 ± 0.19 | 0.98 ± 0.91 | .064 |
| ΔCr (mg/dL) | −0.02 ± 0.13 | 0.10 ± 0.79 | .169 |
| AKI (No.) (%) | 2 (2.3) | 7 (7.4) | .172 |
| Contrast for CTA (mL) (mean) | 95.0 ± 6.9 | 94.0 ± 7.5 | .369 |
| Contrast for DSA (ml) (mean) | / | 93.4 ± 15.7 | / |
| Total contrast (mL) (mean) | 95.02 ± 6.85 | 187.04 ± 15.68 | .000 |

Note:—/ indicates non-applicable.

average, patients with AKI had creatinine level increases: 0.24 ± 0.06 mg/dL (31.0% ± 6.9%) in the CTA group and 1.71 ± 2.42 mg/dL (131.6% ± 160.2%) in the DSA group.

DISCUSSION

This prospective study showed that the additional use of contrast for endovascular treatment after CTA did not increase the incidence of AKI, consistent with the results of previous studies.^{10–15}

Although the study was designed prospectively, we did not expect that the postimaging laboratory studies would be unavailable for patients with mild symptoms who left the hospital early. Loss of patients presents a potential risk of biasing the results. In addition, the prevalence of underlying medical comorbidities, such as atrial fibrillation and heart failure, was higher in the DSA group, which may predispose the patients to develop AKI.

There was no statistically significant difference in AKI incidence between the CTA and DSA groups, though a trend toward a higher incidence of AKI was observed with consecutive, multidose use of contrast (7.4% versus 2.3%). We agree that the benefits of the endovascular treatment most likely outweigh the potential risks of AKI because these benefits were confirmed in 5 prior trials.^{4–8} We do think that controlling the total volume of contrast medium during the endovascular treatment is still necessary.

The definition of AKI varied in previous studies, ranging from an increase in the serum creatinine level of 25%–50% from the baseline level to an absolute increase of 0.3 or 0.5 mg/dL.^{10–15} In the current study, we chose a >25% increase in the serum creatinine level as the threshold for an AKI diagnosis, which was more sensitive than the criterion of a >50% increase or a >0.5-mg/dL increase, and it may have led to a higher incidence of AKI (7.4% in the DSA group) compared with the rate of AKI reported in previous studies (0%–9%) with varying standards.^{10–15}

CONCLUSIONS

This prospective study showed that consecutive, multidose use of contrast for CTA and DSA did not significantly increase the rate of AKI in patients with AIS compared with the 1-time use of contrast for CTA. The trend toward an increased AKI incidence after using more contrast should be further investigated.

REFERENCES

1. Brinjikji W, Demchuk AM, Murad MH, et al. **Neurons over nephrons: systematic review and meta-analysis of contrast-induced nephropathy in patients with acute stroke.** *Stroke* 2017;48:1862–68 CrossRef Medline
2. Ehrlich ME, Turner HL, Currie LJ, et al. **Safety of computed tomographic angiography in the evaluation of patients with acute stroke: a single-center experience.** *Stroke* 2016;47:2045–50 CrossRef Medline

3. Demel SL, Grossman AW, Khoury JC, et al. **Association between acute kidney disease and intravenous dye administration in patients with acute stroke: a population-based study.** *Stroke* 2017;48:835–39 CrossRef Medline
4. Berkhemer OA, Fransen PS, Beumer D, et al. **A randomized trial of intraarterial treatment for acute ischemic stroke.** *N Engl J Med* 2015;372:11–20 CrossRef Medline
5. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. **Endovascular therapy for ischemic stroke with perfusion-imaging selection.** *N Engl J Med* 2015;372:1009–18 CrossRef Medline
6. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. **Randomized assessment of rapid endovascular treatment of ischemic stroke.** *N Engl J Med* 2015;372:1019–30 CrossRef Medline
7. Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. **Thrombectomy within 8 hours after symptom onset in ischemic stroke.** *N Engl J Med* 2015;372:2296–306 CrossRef Medline
8. Saver JL, Goyal M, Bonafe A, et al; SWIFT PRIME Investigators. **Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.** *N Engl J Med* 2015;372:2285–95 CrossRef Medline
9. Rao QA, Newhouse JH. **Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis.** *Radiology* 2006;239:392–97 CrossRef Medline
10. Krol AL, Dzialowski I, Roy J, et al. **Incidence of radiocontrast nephropathy in patients undergoing acute stroke computed tomography angiography.** *Stroke* 2007;38:2364–66 CrossRef Medline
11. Hall SL, Munich SA, Cress MC, et al. **Risk of acute kidney injury associated with neuroimaging obtained during triage and treatment of patients with acute ischemic stroke symptoms.** *J Neurointerv Surg* 2016;8:1231–34 CrossRef Medline
12. Sharma J, Nanda A, Jung RS, et al. **Risk of contrast-induced nephropathy in patients undergoing endovascular treatment of acute ischemic stroke.** *J Neurointerv Surg* 2013;5:543–45 CrossRef Medline
13. Loh Y, McArthur DL, Vespa P, et al. **The risk of acute radiocontrast-mediated kidney injury following endovascular therapy for acute ischemic stroke is low.** *AJNR Am J Neuroradiol* 2010;31:1584–87 CrossRef Medline
14. Lima FO, Lev MH, Levy RA, et al. **Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy.** *AJNR Am J Neuroradiol* 2010;31:817–21 CrossRef Medline
15. Ahmad N, Nayak S, Jadun C, et al. **Mechanical thrombectomy for ischaemic stroke: the first UK case series.** *PLoS One* 2013; 8:e82218 CrossRef Medline